Aligos Therapeutics, Inc. announced that the company remains on track to complete all Phase 2-enabling activities in 2023 for ALG-055009, its thyroid hormone receptor beta (THR-ß) drug candidate for nonalcoholic steatohepatitis (NASH). Dr. Blatt will provide a corporate update and discuss the company's entire pipeline, including ALG-055009, the coronavirus protease inhibitor ALG-097558, and Aligos' hepatitis B portfolio, on January 12, 2023, at 10:30 a.m. PT during the 41st Annual JP Morgan Healthcare Conference in San Francisco. Dr. Blatt's presentation will also be posted on the Aligos website at the time of the conference.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5 USD | -1.59% | -7.42% | -24.70% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.70% | 39.05M | |
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- ALGS Stock
- News Aligos Therapeutics, Inc.
- Aligos Therapeutics, Inc. on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009